openPR Logo
Press release

Major Milestone Achieved – EXCOR® Pediatric HDE Application Under Review

04-13-2011 05:22 PM CET | Health & Medicine

Press release from: Berlin Heart

Major Milestone Achieved – EXCOR® Pediatric HDE Application

The Berlin Heart Group reported today that the results of the US IDE Trial for the Berlin Heart EXCOR® Pediatric Ventricular Assist Device have been submitted to the FDA in an HDE application. The FDA has informed the company that the application is officially under review and that a tentative panel date has been scheduled.

The study, which enrolled the first patient in November 2007, is the first prospective clinical trial ever conducted to investigate the safety and benefit of a Ventricular Assist Device in the pediatric population. Full enrolment of the trial took approximately thirty-three months.

The Berlin Heart EXCOR® Pediatric VAD is a system for mechanical support of the heart in end-stage heart failure patients. It has been specifically designed for use in pediatric patients of all age groups ranging from newborns to teenagers. The system is intended to bridge patients awaiting heart transplantation until a donor heart becomes available, but has also been used successfully as a bridge to recovery when a patient’s heart was able to recover and work on its own again.

Dr. Stefan Thamasett, CEO of the Berlin Heart group commented “We are excited about completing this important study. This milestone brings us closer to our goal of making this device more readily available for sick children in the US and being able to offer children with heart failure every possible treatment option. This is an outstanding achievement for the whole Berlin Heart team. We especially thank our study sites, our investigators and most importantly, the families of the children that participated in the study.”

The following US centers participated in the IDE study:

Arkansas Children’s Hospital (AR)
Boston Children’s Hospital (MA)
Children’s Healthcare of Atlanta (GA)
Children’s Hospital of Wisconsin (WI)
The Children’s Hospital of Denver (CO)
Lucille Packard Children’s Hospital at Stanford (CA)
Mott Children’s Hospital (MI)
Mount Sinai Hospital (NY)
Pittsburgh Children’s Hospital (PA)
Riley Children’s Hospital (IN)
Seattle Children’s Hospital (WA)
St. Louis Children’s Hospital (MO)
Texas Children’s Hospital (TX)
Children’s Hospital at the University of Alabama at Birmingham (AL)
University of Minnesota at Fairview (MN)

Implants of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device in the US for BTT patients are continuing under a Continued Access Protocol approved by the FDA while the HDE application is under review.

About Berlin Heart:
Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices for patients of every age and body size. The company offers pumps, cannulae, and external components for internal and external use to stabilise cardiac activity in acutely ill patients. Its products are market leaders in their respective segments in Germany and in Europe.

The company also manufactures the implantable left ventricular assist device INCOR®, which has been designed for long-term application in adult patients. The longest the device has supported a patient so far is more than five years. INCOR® is not FDA-approved, but widely used in Europe.

Berlin Heart Inc., the company’s US subsidiary, was founded in 2005 to support the North American centers. Further product information is available from the company website:
www.berlinheart.com.

Berlin Heart Inc.
200 Valleywood
Suite A500
The Woodlands, TX 77380

Berlin Heart GmbH
Marketing & PR
Wiesenweg 10
12247 Berlin, Germany

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Major Milestone Achieved – EXCOR® Pediatric HDE Application Under Review here

News-ID: 170816 • Views:

More Releases from Berlin Heart

100th EXCOR® Implantation in Spain
100th EXCOR® Implantation in Spain
In March 2015 the clinic La Paz Madrid recorded a particular success: After ten years of EXCOR® therapy in Spain, the 100th implantation of the Berlin Heart was performed. La Paz is one of the leading Spanish hospitals for pediatric heart surgery. Almost simultaneously in another clinic in Madrid the 101st implantation took place and further implantations followed. The clinics in Spain benefit from an excellent service by Palex Medical
The 1,500th child supported by the Berlin Heart ventricular assist device has been transplanted
The 1,500th child supported by the Berlin Heart ventricular assist device has be …
The EXCOR® Pediatric ventricular assist device (VAD) has been implanted in more than 1,500 children worldwide to save their lives. In June 2014 for the 1,500th time, the EXCOR® Pediatric device was implanted to save the life of a child: a 14-year-old boy from Hong Kong who was suffering from dilated cardiomyopathy since the age of four was supported with the life-saving device. Up to that point the teenager had

More Releases for Children’s

Neuroblastoma Treatment Market Significantly Stepping towards the Success Till 2 …
The global Neuroblastoma Treatment market size is projected a CAGR of 6.8% during 2021-2027. The rising prevalence of the disease is expected to increase demand for treatment. With the ongoing COVID-19 pandemic, healthcare staff are taking extra precautions and increasing therapy to safeguard children with cancer from infection. The worldwide neuroblastoma treatment market is expected to be driven by the increasing designation of orphan medicines for treating malignancies such as
Neuroblastoma Treatment Market Top Key Players- Seattle Children’s, CureSearch …
Zion Market Research published a new 110+ pages industry research “Neuroblastoma Treatment Market: Global Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015- 2021” is exhaustively researched and analyzed in the report to help market players to improve their business tactics and ensure long-term success. The authors of the report have used easy-to-understand language and uncomplicated statistical images but provided thorough information and detailed data on the Global Neuroblastoma
Global neuroblastoma treatment Market Report 2019 Companies included Seattle Chi …
#7th Edition neuroblastoma treatment market report recently has been published by market reports company. It features comprehensive market outlook based on historic data from 2013 to 2018 and estimated market trends during the forecast period from 2018 to 2026. To access complete insights of global neuroblastoma treatment market report: sales@marketreportscompany.com The neuroblastoma treatment market delivers a wide array of primary and secondary data with respect to regional and global market. In-depth
Global Online Children’s Apparel Market Size, Industry Status, Growth Opportun …
The market for Online Children’s Apparel is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Online Children’s Apparel Market” which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore, an anticipated growth
COMO® Reimagines Children’s Building
Press Release May 9, 2018, Munich, Germany- COMO®, the revolutionary new building blocks helping to inspire creative children worldwide, is live on global crowdfunding platform Kickstarter and raising funds to bring the project to life. COMO® represents the next generation of building blocks for children and enthusiasts alike. The best thing for parents and children is to build according to their own ideas and imagination. COMO® stands for ‘COmbine
New children’s book series: „Schnatter and Lieschen“ take over children’ …
Two ducks are taking over children’s playrooms: Schnatter and Lieschen. These two brand new characters are the creations of author Claudia Raab (50) and illustrator Peter Oedekoven (whose work includes Disney's “Dinosaur” and “Maya the Bee Movie”). In volume 1, which has just been published, Schnatter and Lieschen celebrate their name day – and the two little ducks invite all their animal friends. For example there is Eiei, the chicken, who